TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP)
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of different doses of
TA-8995, a cholesteryl ester transfer protein (CETP) inhibitor, on the elevation of
high-density lipoprotein cholesterol (HDL-C) and reduction of low-density lipoprotein
cholesterol (LDL-C), alone and in combination with statin therapy.
The secondary objectives of this study are to determine the safety and tolerability of
TA-8995 in patients with mild dyslipidaemia.